Skip to Content

GTx to Present Additional Efficacy and Safety Analyses from the Toremifene 80 mg Phase III ADT Clinical Trial at the Annual Meeting of the American Society for Bone and Mineral Research

MEMPHIS, Tenn.--(BUSINESS WIRE)--Sep 10, 2008 - GTx, Inc. (Nasdaq: GTXI) announced that additional efficacy and safety analyses from the Phase III clinical trial evaluating toremifene 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) in men with advanced prostate cancer will be presented September 16th in an oral session at the 2008 Annual Meeting of the American Society for Bone and Mineral Research being held in Montreal, Canada.

The presentation will highlight bone turnover marker data as well as an additional supportive safety analysis regarding the effect of toremifene 80 mg in men with advanced prostate cancer on ADT. -0-

Abstract:                    "C-telopeptide and Bone Alkaline
                              Phosphatase Predict Morphometric
                              Vertebral Fracture Risk in a Pivotal
                              Phase III trial of Toremifene in Men on
Session Number:              47
Session Title:               Osteoporosis Treatment (clinical) IV:
                              John H. Carstens Memorial Session
Presentation Start/End Time: Tuesday, Sept. 16, 2008, 11:15 a.m. -
                              11:30 a.m. ET
Location:                    Palais des congres de Montreal, Room 517

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. GTx is developing toremifene citrate, a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a completed pivotal Phase III clinical trial evaluating toremifene 80 mg for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, an ongoing pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. In 2006, GTx and Ipsen Group entered into a development and collaboration agreement for toremifene citrate in all indications except breast cancer for Europe and the Commonwealth of Independent States (CIS). GTx will file for marketing approval and, if approved, plans to commercialize toremifene 80 mg in the United States. In December 2007, GTx and Merck & Co., Inc. formed a collaboration to discover and develop selective androgen receptor modulators (SARMs), a new class of drugs with the potential to treat sarcopenia, which is the loss of skeletal muscle mass resulting in reduced physical strength and ability to perform activities of daily living, cancer cachexia (muscle wasting), as well as other musculoskeletal conditions. Merck and GTx are conducting several Phase I and Phase II clinical trials evaluating multiple SARM product candidates including Ostarine(TM) (also designated as MK-2866) for sarcopenia. Ostarine is also in a Phase II clinical trial for cancer cachexia which will be completed in 2008. Merck and GTx are evaluating additional muscle loss indications for potential SARM clinical development. GTx also is developing its preclinical compounds, GTx-758, an oral LH inhibitor for advanced prostate cancer, and GTx-878, an estrogen receptor beta agonist for the treatment of benign prostatic hyperplasia and chronic prostatitis.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx and its collaboration partners will not be able to commercialize their product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not able to obtain required regulatory approvals to commercialize product candidates; (iii) clinical trials being conducted by GTx and its collaboration partners may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's quarterly report on Form 10-Q filed August 5, 2008 contain under the heading, "Risk Factors," a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


GTx, Inc.
McDavid Stilwell, 901-523-9700
Director, Corporate Communications & Financial Analysis


Posted: September 2008